Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $23.00.
IOVA has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Monday, August 12th. StockNews.com upgraded shares of Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th. Finally, Piper Sandler downgraded shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $19.00 to $10.00 in a report on Monday, July 29th.
Get Our Latest Research Report on IOVA
Institutional Inflows and Outflows
Iovance Biotherapeutics Price Performance
IOVA opened at $9.92 on Friday. The firm has a market cap of $2.78 billion, a P/E ratio of -5.51 and a beta of 0.62. Iovance Biotherapeutics has a 1-year low of $3.27 and a 1-year high of $18.33. The company has a 50 day simple moving average of $10.27 and a two-hundred day simple moving average of $9.93.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01. The business had revenue of $31.11 million during the quarter, compared to analyst estimates of $24.59 million. Iovance Biotherapeutics had a negative return on equity of 65.04% and a negative net margin of 1,343.27%. Iovance Biotherapeutics’s revenue for the quarter was up 12969.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.47) EPS. Equities analysts anticipate that Iovance Biotherapeutics will post -1.26 earnings per share for the current year.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
Featured Stories
- Five stocks we like better than Iovance Biotherapeutics
- How to Calculate Inflation Rate
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Industrial Products Stocks Investing
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- What Are Some of the Best Large-Cap Stocks to Buy?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.